entertainment -WSS

entertainment

author：Wikipedia 2025-09-27 12:48:28 - browse：4737

The FDA building -- First Opinion coverage from STAT — Adobe

A panel of expert advisers to the Food and Drug Administration on Friday voted in favor of expanding the use of CAR-T therapy in blood cancer, despite concerns about the powerful treatment’s side effects.

The group voted 11-0 that the benefits of Carvykti, a CAR-T medicine from Johnson & Johnson and Legend Biotech, outweighed its risk for patients with multiple myeloma whose disease has persisted despite initial treatment. The same panel voted 8-3 in favor of Abecma, from Bristol Myers Squibb and 2seventy Bio, for multiple myeloma patients who’ve received at least two lines of therapy. Currently both medicines are approved only for patients who have been treated for myeloma with four or more medications.

In clinical trials, each drug proved to significantly delay disease progression compared to standard therapy. But zooming in on the data, the FDA observed an alarming imbalance of deaths in the early months of both studies, finding that more patients in the CAR-T group died of myeloma or side effects than those receiving the standard of care.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Sage considers ways to reduce costs following FDA rejection

hotspot

WSS

With competition flaring, obesity drug hits goal in liver disease study

A new nitrogen execution bill also undermines medical licensing

Pennsylvania man bitten on the head by bear during attack in his garage

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

Mexico finds 491 migrants being held at vacant lot, almost all are from Guatemala

McConnell is warmly embraced by Kentucky Republicans amid questions about his health

entertainment

entertainment

focus

Medicare details structure of new drug price negotiation program

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

Dobbs anniversary: the lost opportunity of abortion as health care

Tuberculosis patients need more than just free medication

Peter Hotez and the public health issue of online harassment

'Brian's Song' at 50 still offers lessons about cancer for today

The cancer drug shortage isn’t new — and neither are the solutions

Alabama IVF ruling threatens families facing fatal genetic disease

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

With heat waves through August, officials warn of health risks

explore

How CRISPR works, explained in two minutes

Why palliative psychiatry is worth discussing

R1 RCM gets $5.8 billion buyout offer from private equity firm

The Harvard botanist who searched for psychedelics in the Amazon

Alabama frozen embryo ruling has major implications for IVF clinics

R1 RCM gets $5.8 billion buyout offer from private equity firm

Wikipedia

hotspot

leisure time

hotspot